pyridinolcarbamate has been researched along with Bright Disease in 1 studies
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lagrue, G | 1 |
| Hirbec, G | 1 |
| Moisy, M | 1 |
| Sternberg, M | 1 |
| Blanc, C | 1 |
1 other study available for pyridinolcarbamate and Bright Disease
| Article | Year |
|---|---|
[Action of pyridinol carbamate on hetero-immune Masugi nephritis in the rat (author's transl)].
Topics: Animals; Capillary Permeability; Carbamates; Disease Models, Animal; Glomerulonephritis; Immune Sera | 1976 |